18:19 , Oct 18, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays, diagnostic assays; plasma markers Circulating CD4 + T cells specific for full-length C-peptide could be used for early diagnosis of Type I diabetes. In peripheral blood samples from patients with recent-onset Type...
22:23 , Oct 11, 2018 |  BC Innovations  |  Translation in Brief

Cancer antigens from RNA edits

A team from Immatics Biotechnologies GmbH and University of Texas MD Anderson Cancer Center has shown that cancer antigens generated via post-transcriptional RNA editing could further broaden the target space for immunotherapies. The study ,...
17:13 , Aug 23, 2018 |  BC Innovations  |  Translation in Brief

The self-destructing pancreas

A pair of independent papers from researchers from Washington University School of Medicine in St. Louis and Institut National de la Santé et de la Recherche Médicale (INSERM) illustrate how pancreatic β cells may contribute...
20:07 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Nohla adds $11M to series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised an additional $11 million on June 11 in the second close of a series B financing, bringing the round’s total to $56 million. New investors...
16:42 , Jul 6, 2018 |  BC Week In Review  |  Company News

Athenex Announces Two China Deals Plus $100M Raise

Athenex Inc. (NASDAQ:ATNX) entered into a pair of deals with Chinese partners on a newsy July 2 that also saw the biotech raise $100 million in equity and debt. The company said it is forming...
23:18 , Jul 2, 2018 |  BC Extra  |  Company News

Athenex announces two China deals plus $100M raise

Athenex Inc. (NASDAQ:ATNX) entered into a pair of deals with Chinese partners on a newsy Monday that also saw the biotech raise $100 million in equity and debt. The company said it is forming a...
02:30 , May 18, 2018 |  BC Week In Review  |  Financial News

Arch leads Nohla's $45M series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised $45 million on May 15 in a series B round led by existing investor Arch Venture Partners. Also participating were new investors Fidelity Management and...
20:54 , May 15, 2018 |  BC Extra  |  Financial News

Arch leads Nohla's $45M series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised $45 million in a series B round led by existing investor Arch Venture Partners. Also participating were new investors Fidelity Management and Celgene Corp. (NASDAQ:CELG)...
23:26 , Mar 21, 2018 |  BioCentury  |  Finance

Seeking domestic partners

The syndicate behind TCR2 Therapeutics Inc.’s $125 million series B round includes a bevy of Chinese investors who could provide access to development and manufacturing partners in China. 6 Dimensions Capital and Curative Ventures led...
17:50 , Mar 13, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; bioinformatics screen A yeast-based method coupled with bioinformatics could help identify tumor antigens that stimulate orphan TCRs for use in cancer T cell therapies and vaccines. The method involves screening TCRs derived...